Vai al contenuto principale
xMedica

NCT07919678ClinicalTrials.gov

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…

Fase 3656 partecipanti ricercati40 centri2 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.

How this score is built
  • Enrolment28/40

    656 participants (target)

  • Site count19/25

    40 sites

  • Country count7/15

    2 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    Pfizer has led 630 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

Patologie

  • Obesity
  • Overweight
  • Osteoarthritis of the Knee

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Adults 18 years of age or older, or the minimum age of consent according to local regulations. * Body mass index of at least 27 kg/m² at Screening. * Currently meets American College of Rheumatology (ACR) Criteria for knee OA. * Pain due to knee OA. * Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3. * Willingness to complete the required analgesic washout. * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Self-reported body weight increase or decrease greater than 5% within 90 days before Screening. * History of diabetes or Screening laboratory findings indicative of diabetes. * Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease. * Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. * Significant active or unstable psychiatric disorder. * Condition or knee disorder that could confound assessment of target-knee pain. * Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study. * Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment. * Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo. * Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento656 partecipanti ricercati

Sponsor e collaboratori

  • Pfizer Sponsor

Bracci e interventi

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo as subcutaneous injection

  • Arm 1: Berobenatide Once MonthlyEXPERIMENTAL

    Participants will receive berobenatide by subcutaneous injection.

  • Arm 2: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

  • Arm 3: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

Interventi

  • Farmaco Berobenatide

    Subcutaneous Injection

  • Altro Placebo

    Subcutaneous Injection

Esiti misurati

  1. Esito primario

    Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score

    Orizzonte temporale Baseline and Week 52

  2. Esito secondario

    Percent change from baseline in Body Weight

    Orizzonte temporale Baseline and Week 52

  3. Esito secondario

    Change From Baseline in High-Sensitivity C-Reactive Protein

    Orizzonte temporale Baseline and Week 52

  4. Esito secondario

    Change from baseline in WOMAC Physical Function Subscale score

    Orizzonte temporale Baseline and Week 52

  5. Esito secondario

    Percentage of participants with ≥50% reduction in the WOMAC pain subscale score

    Orizzonte temporale Baseline and Week 52

  6. Esito secondario

    Percentage of participants with ≥30% reduction in the WOMAC pain subscale score

    Orizzonte temporale Baseline and Week 52

  7. Esito secondario

    Proportion of participants with utilization of protocol specified pain medication during the washout period

    Orizzonte temporale Baseline and Week 52

  8. Esito secondario

    Amount of protocol specified pain medication during the washout period

    Orizzonte temporale Baseline and Week 52

  9. Esito secondario

    Change from baseline in WOMAC stiffness score

    Orizzonte temporale Baseline and Week 52

  10. Esito secondario

    Change from baseline in WOMAC total score

    Orizzonte temporale Baseline and Week 52

  11. Esito secondario

    Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score

    Orizzonte temporale Baseline and Week 52

  12. Esito secondario

    Proportion of participants meeting OMERACT-OARSI

    Orizzonte temporale Baseline and Week 52

  13. Esito secondario

    Change from baseline in Average Pain Intensity-Numerical Rating Score

    Orizzonte temporale Baseline and Week 52

  14. Esito secondario

    Change from baseline in Worst Pain Intensity -Numerical Rating Score

    Orizzonte temporale Baseline and Week 52

  15. Esito secondario

    Change from baseline in SF-36 domain scales and component summary scales

    Orizzonte temporale Baseline and Week 52

  16. Esito secondario

    Change from baseline in Body Weight

    Orizzonte temporale Baseline and Week 52

  17. Esito secondario

    Change from Baseline in Body Mass Index

    Orizzonte temporale Baseline and Week 52

  18. Esito secondario

    Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Orizzonte temporale Baseline and Week 52

  19. Esito secondario

    Number of Participants with Serious Adverse Events (SAE)

    Orizzonte temporale Baseline and Week 52

  20. Esito secondario

    Number of Participants with AE leading to permanent discontinuation from study intervention or study

    Orizzonte temporale Baseline and Week 52

  21. Esito secondario

    Number of Participants with Adverse Events of Special Interest (AESI)

    Orizzonte temporale Baseline and Week 52

  22. Esito secondario

    Number of Participants with Clinical laboratory abnormalities

    Orizzonte temporale Baseline and Week 52

  23. Esito secondario

    Change from baseline in timed walking distance at Week 52

    Orizzonte temporale Baseline and Week 52

  24. Esito secondario

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function

    Orizzonte temporale Baseline and Week 52

  25. Esito secondario

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain

    Orizzonte temporale Baseline and Week 52

  26. Esito secondario

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function

    Orizzonte temporale Baseline and Week 52

  27. Esito secondario

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain

    Orizzonte temporale Baseline and Week 52

  28. Esito secondario

    Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score

    Orizzonte temporale Baseline and Week 52

  29. Esito secondario

    Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score

    Orizzonte temporale Baseline and Week 52

  30. Esito secondario

    Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score

    Orizzonte temporale Baseline and Week 52

  31. Esito secondario

    Change From Baseline in WPAI:GH Work productivity loss score

    Orizzonte temporale Baseline and Week 52

  32. Esito secondario

    Change From Baseline in WPAI:GH Activity impairment score

    Orizzonte temporale Baseline and Week 52

  33. Esito secondario

    Change From Baseline in Systolic Blood Pressure (SBP)

    Orizzonte temporale Baseline and Week 52

  34. Esito secondario

    Change From Baseline in Diastolic Blood Pressure (DBP)

    Orizzonte temporale Baseline and Week 52

  35. Esito secondario

    Change From Baseline in Total Cholesterol

    Orizzonte temporale Baseline and Week 52

  36. Esito secondario

    Change From Baseline in High-density lipoprotein cholesterol (HDL-C)

    Orizzonte temporale Baseline and Week 52

  37. Esito secondario

    Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)

    Orizzonte temporale Baseline and Week 52

  38. Esito secondario

    Change from baseline in Non-HDL Cholesterol

    Orizzonte temporale Baseline and Week 52

  39. Esito secondario

    Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol

    Orizzonte temporale Baseline and Week 52

  40. Esito secondario

    Change from baseline in Triglycerides

    Orizzonte temporale Baseline and Week 52

Date

Date
Data di inizio26 ottobre 2026 (effettiva)
Conclusione primaria22 agosto 2028 (stimata)
Conclusione10 ottobre 2028 (stimata)
Prima pubblicazione5 novembre 2026 (effettiva)
Ultimo aggiornamento5 novembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaottobre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

7 centri stanno reclutando

Canada

Canada
StrutturaCittàStato o regioneStato
Bluewater Clinical Research Group Inc.SarniaOntarioNon ancora in reclutamento

United States

United States
StrutturaCittàStato o regioneStato
Albuquerque Clinical Trials, Inc.AlbuquerqueNew MexicoNon ancora in reclutamento
Charlottesville Medical Research Center, LLCCharlottesvilleVirginiaNon ancora in reclutamento
Northwestern University Feinberg School Of MedicineChicagoIllinoisNon ancora in reclutamento
Great Lakes Clinical Trials, LLC dba Flourish ResearchChicagoIllinoisNon ancora in reclutamento
Northwestern MedicineChicagoIllinoisNon ancora in reclutamento
Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)ChicagoIllinoisNon ancora in reclutamento
Northwestern Memorial Hospital, Investigational Drug ServiceChicagoIllinoisNon ancora in reclutamento
Clinical Research of West Florida, Inc.ClearwaterFloridaNon ancora in reclutamento
Skylight Health ResearchColorado SpringsColoradoNon ancora in reclutamento
Mercy Family ClinicDallasTexasNon ancora in reclutamento
Universal Axon Clinical Research LLCDoralFloridaIn reclutamento
Altoona Center For Clinical ResearchDuncansvillePennsylvaniaIn reclutamento
Headlands Research California, LLCEscondidoCaliforniaNon ancora in reclutamento
Profound Research LLCFarmington HillsMichiganIn reclutamento
Cedar Health ResearchFort WorthTexasNon ancora in reclutamento
Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite QuarryNorth CarolinaNon ancora in reclutamento
BRCR Global LouisianaGretnaLouisianaNon ancora in reclutamento
JCCT-JUNO NW HoustonHoustonTexasNon ancora in reclutamento
Westside Center for Clinical ResearchJacksonvilleFloridaNon ancora in reclutamento
Activian Clinical ResearchKingwoodTexasNon ancora in reclutamento
Renstar Medical ResearchLady LakeFloridaNon ancora in reclutamento
Monroe Biomedical ResearchMonroeNorth CarolinaIn reclutamento
AMR ClinicalNormanOklahomaNon ancora in reclutamento
Renstar Medical ResearchOcalaFloridaNon ancora in reclutamento
Prospective Research Innovations Inc.Rancho CucamongaCaliforniaNon ancora in reclutamento
Accellacare - SalisburySalisburyNorth CarolinaNon ancora in reclutamento
Consano Clinical Research, LLCShavano ParkTexasNon ancora in reclutamento
Revive Research Institute, Inc.Sterling HeightsMichiganIn reclutamento
Clinical Research AtlantaStockbridgeGeorgiaNon ancora in reclutamento
Clinical Research of West Florida, Inc.TampaFloridaNon ancora in reclutamento
AMR ClinicalTempeArizonaNon ancora in reclutamento
DM Clinical ResearchTomballTexasNon ancora in reclutamento
Solace Clinical ResearchTustinCaliforniaNon ancora in reclutamento
Velocity Clinical Research, WacoWacoTexasNon ancora in reclutamento
Elevate Clinical ResearchWichitaKansasNon ancora in reclutamento
Delaney RadiologistWilmingtonNorth CarolinaIn reclutamento
AccellacareWilmingtonNorth CarolinaIn reclutamento
North Georgia Internal MedicineWoodstockGeorgiaNon ancora in reclutamento
North Georgia Clinical Research, LLCWoodstockGeorgiaNon ancora in reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.

Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.